Preparation of a steroid-oxazole-1,2′-[1,3]oxazete] derivative: biological and theoretical evaluation of its interaction with a kinase protein (CK2)

被引:12
作者
Lauro, Figueroa-Valverde [1 ]
Francisco, Diaz-Cedillo [2 ]
Marcela, Rosas-Nexticapa [3 ]
Virginia, Mateu-Armand [3 ]
Gomez Eduardo, Pool [1 ]
Maria, Lopez-Ramos [1 ]
Lenin, Hau-Heredia [1 ]
Alondra, Alfonso-Jimenez [1 ]
Jhair, Cabrera-Tuz [1 ]
机构
[1] Univ Autonomous Campeche, Fac Chem Biol Sci, Lab Pharmacochem, Av Agustin Melgar S-N, Campeche 24039, CAM, Mexico
[2] Inst Politecn Nacl, Escuela Nacl Ciencias Biol, Prol Carpio & Plan Ayala S-N, Mexico City 11340, DF, Mexico
[3] Univ Veracruzana, Fac Nutr, Med & Odontologos S-N, Xalapa 91010, Veracruz, Mexico
来源
SN APPLIED SCIENCES | 2019年 / 1卷 / 04期
关键词
Steroid; Infarct; Ischemia; Kinase protein; ISCHEMIA/REPERFUSION; ACTIVATION; INHIBITOR; NITRATION;
D O I
10.1007/s42452-019-0378-7
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The aim of this study was synthesizing a steroid-oxazole-oxazete derivative (4) to evaluate their biological activity in vitro. The first stage was achieved by the preparation of a steroid-oxazole-1,2'-[1,3]oxazete] derivative using a series of reactions such as; (1) addition; (2) nitration and (3) cyclization. Then, the biological activity of steroid analog against infarct area was evaluated on an ischemia/reperfusion model using quinalizarin as a control. In addition, the interaction of steroid derivative with kinase protein (CK2) was evaluated using a docking model. The results showed a decrease infarct area (0.001 nM] in a similar form that quinalizarin. In addition, the theoretical analysis suggests that steroid derivative could interact with some aminoacid residues (GIn(86), Lys(96), Leu(97), Leu(98)) of 3FL5 protein surface. All these data indicate that steroid derivative can decrease the infarct area via CK2 inhibition.
引用
收藏
页数:12
相关论文
共 48 条
  • [1] Acute Myocardial Infarction
    Anderson, Jeffrey L.
    Morrow, David A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (21) : 2053 - 2064
  • [2] [Anonymous], 1999, REV ARG CARDIOL
  • [3] Protein kinase activation and myocardial ischemia/reperfusion injury
    Armstrong, SC
    [J]. CARDIOVASCULAR RESEARCH, 2004, 61 (03) : 427 - 436
  • [4] Canales Luis, 2011, Org Med Chem Lett, V1, P9, DOI 10.1186/2191-2858-1-9
  • [5] CARMICHAEL DF, 1982, J BIOL CHEM, V257, P440
  • [6] CORKINS HG, 1980, TETRAHEDRON LETT, V21, P2025
  • [7] Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2
    Cozza, Giorgio
    Mazzorana, Marco
    Papinutto, Elena
    Bain, Jenny
    Elliott, Matthew
    Di Maira, Giovanni
    Gianoncelli, Alessandra
    Pagano, Mario A.
    Sarno, Stefania
    Ruzzene, Maria
    Battistutta, Roberto
    Meggio, Flavio
    Moro, Stefano
    Zagotto, Giuseppe
    Pinna, Lorenzo A.
    [J]. BIOCHEMICAL JOURNAL, 2009, 421 : 387 - 395
  • [8] Computational approaches for predicting CYP-related metabolism properties in the screening of new drugs
    Crivori, P.
    Poggesi, I.
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2006, 41 (07) : 795 - 808
  • [9] SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules
    Daina, Antoine
    Michielin, Olivier
    Zoete, Vincent
    [J]. SCIENTIFIC REPORTS, 2017, 7
  • [10] Pharmacological preconditioning with resveratrol:: role of CREB-dependent Bcl-2 signaling via adenosine A3 receptor activation
    Das, S
    Cordis, GA
    Maulik, N
    Das, DK
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2005, 288 (01): : H328 - H335